Articles related to CLINICAL TRIALS

Perelman School of Medicine’s David Teachey, MD, reviews outcomes and implications from two recent Children’s Oncology Group trials and describes current research with daratumumab and CAR T-cell therapy.

Phase 1 trial using an autologous CAR-T cell therapy that targets the oncofetal antigen Claudin-6 (CLDN6) — and CARVac (BioNTech), a CLDN6-encoding mRNA-based vaccine designed to enhance CAR T-cell activity. Data show encouraging clinical activity for an investigational CAR T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.

Mirvetuximab soravtansine generated an objective response in nearly 1/3 of patients participating. That compares with response rates in the single digits for current treatments in patients whose ovarian cancer doesn’t respond to platinum-based chemotherapy.

Neo-adjuvant therapy with nivolumab and ipilimumab is associated with a high pCR rate in ptsd with MSI/dMMR resectable OGA.

The phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy significantly improved OS compared to chemotherapy alone in patients with previously untreated advanced esophageal squamous cell carcinoma.

Although vaccinations to the arm can still prevent serious illness, their ability to ward off infection completely has been diminished. And part of the reason may be the location of the vaccines, which some scientists now want to change by delivering inoculations to the site where the virus first makes contact: the nose. Three separate nasal sprays, now in advanced trials, could trigger stronger immune responses in people who have COVID-19.